Overexpression of minichromosome maintenance 2 predicts poor prognosis in patients with gastric cancer.
We examined the expression of minichromosome maintenance 2 (MCM2) in gastric cancer and adjacent normal tissues and estimated the possible value of MCM2 as a novel prognostic marker. Using real-time PCR, western blotting and immunohistochemistry, we examined the expression of MCM2 in gastric carcinoma and paired normal gastric mucosa. Statistical analysis of the expression of MCM2 mRNA and protein in gastric cancer and normal tissues was performed to evaluate the relationship between MCM2 expression and clinicopathological characteristics in gastric cancer. The expression of MCM2 mRNA and protein in gastric carcinomas was significantly higher compared to that in normal gastric mucosa (P=0.04). Immunohistochemistry analysis showed that MCM2 expression was significantly up-regulated in tumor and metastastic lymph node tissues compared with the corresponding non-cancerous mucosa (P<0.05). Positive expression of MCM2 was significantly associated with patient age, T category and the presence of lymph node metastasis (P<0.05). There were no differences between MCM2 expression and gender, tumor size, tumor location, M category, International Union Against Cancer (UICC) stage, vessel invasion and tumor differentiation. Patients with negative tumor MCM2 expression displayed a better survival time than those with positive MCM2 expression (P<0.05). Survival analysis showed that positive MCM2 expression (P<0.05), T stage (P<0.05) and N stage (P<0.05) were independent prognostic factors for disease-free survival (DFS) and overall survival (OS). Our data suggest that MCM2 could serve as a novel prognostic biomarker in gastric carcinoma.